There has been a lot of curiosity within the biologics industry regarding how the "patent dance" procedures of the Biologics Price Competition and Innovation Act would operate. [1] This interest was piqued in July 2014 when Sandoz Inc.'s biosimilar application for a biosimilar of Amgen Inc.'s Neupogen was the first accepted by FDA under section 351 of the Public Health Service Act .
http://ift.tt/1uwnRsB
http://ift.tt/1uwnRsB
No comments:
Post a Comment